Biosimilar Equal to Natalizumab for Relapsing-Remitting MS Biosimilar Equal to Natalizumab for Relapsing-Remitting MS

A novel biosimilar matches natalizumab in terms of efficacy, safety, and immunogenicity in patients with relapsing remitting multiple sclerosis, results from a new phase 3 trial show.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news